Asfand Yar Cheema/LinkedIn
Sep 4, 2025, 22:00
Asfand Yar Cheema at SOHO 2025: PSM Cohort Study on GLP-1 Agonist Therapy Key Clinical Outcomes for Polycythemia Vera
MPN Hub shared on X:
”CONGRESS | SOHO 2025 | PRESENTATION
Asfand Yar Cheema, Cleveland Clinic
Presents results from a PSM cohort study evaluating the association of GLP-1 agonist therapy and key clinical outcomes in Polycythemia Vera.
GLP-1 agonist therapy is associated with significantly reduced risks of all-cause mortality, myelofibrosis progression, VTE, healthcare utilization, AKI, and ischemic stroke/TIA.
Randomized controlled trials are required to confirm GLP-1 agonist safety and efficacy in PV.
Follow our live feed for more updates.”
Find more slides in the gallery.
All on Hemostasis and Thrombosis from SOHO 2025 featured in Hemostasis Today.
-
Aug 6, 2026, 07:55Tom Tang: Why is Asymptomatic DVT More Dangerous?
-
Aug 6, 2026, 07:20Mohammed Anas: Vitamin B12 Is Something You Cannot Afford to Ignore
-
Aug 6, 2026, 07:09Domenico Girelli: Why Hemoglobin Alone Is Not Enough Before Surgery
-
Aug 6, 2026, 06:58Rob Mac Sweeney: Traumatic DIC – A Modern Review
-
Aug 6, 2026, 06:49Mukhyaprana Prabhu: Advancing Precision Biomarkers in Systemic Lupus Erythematosus
-
Aug 6, 2026, 05:53Gender-Affirming Hormone Therapy and Thrombosis – RPTH Journal
-
Aug 6, 2026, 04:58Shamee Shastry: Advancing Precision in Massive Bleed Management
-
Aug 6, 2026, 01:21Orly Leiva: High-Output Heart Failure Signals Disease Progression in PV and ET
-
Aug 5, 2026, 23:46Recommended ESC Congress Sessions for the ESC Working Group on Thrombosis